Biltmore Family Office LLC Purchases 1,894 Shares of Johnson & Johnson (NYSE:JNJ)

Biltmore Family Office LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 13.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,146 shares of the company’s stock after buying an additional 1,894 shares during the period. Biltmore Family Office LLC’s holdings in Johnson & Johnson were worth $2,360,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Kinsale Capital Group Inc. lifted its holdings in Johnson & Johnson by 26.6% during the second quarter. Kinsale Capital Group Inc. now owns 37,870 shares of the company’s stock worth $5,535,000 after buying an additional 7,946 shares during the period. GEM Asset Management LLC lifted its holdings in Johnson & Johnson by 6.2% during the second quarter. GEM Asset Management LLC now owns 2,895 shares of the company’s stock worth $423,000 after buying an additional 169 shares during the period. Studio Investment Management LLC lifted its holdings in Johnson & Johnson by 1.3% during the second quarter. Studio Investment Management LLC now owns 29,141 shares of the company’s stock worth $4,259,000 after buying an additional 373 shares during the period. Vaughan David Investments LLC IL lifted its holdings in Johnson & Johnson by 1.6% during the second quarter. Vaughan David Investments LLC IL now owns 307,565 shares of the company’s stock worth $44,954,000 after buying an additional 4,751 shares during the period. Finally, Carson Advisory Inc. lifted its holdings in Johnson & Johnson by 12.0% during the second quarter. Carson Advisory Inc. now owns 11,357 shares of the company’s stock worth $1,660,000 after buying an additional 1,215 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 0.1 %

JNJ stock opened at $164.64 on Friday. The firm has a market cap of $396.24 billion, a PE ratio of 10.26, a PEG ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm’s 50 day moving average price is $159.17 and its 200-day moving average price is $154.00. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.80 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday. The Goldman Sachs Group decreased their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. TD Securities decreased their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 30th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.